128 related articles for article (PubMed ID: 35568131)
1. Inhibition of serine/arginine-rich protein kinase-1 (SRPK1) prevents cholangiocarcinoma cells induced angiogenesis.
Supradit K; Boonsri B; Duangdara J; Thitiphatphuvanon T; Suriyonplengsaeng C; Kangsamaksin T; Janvilisri T; Tohtong R; Yacqub-Usman K; Grabowska AM; Bates DO; Wongprasert K
Toxicol In Vitro; 2022 Aug; 82():105385. PubMed ID: 35568131
[TBL] [Abstract][Full Text] [Related]
2. Serine-arginine-rich protein kinase-1 inhibition for the treatment of diabetic retinopathy.
Malhi NK; Allen CL; Stewart E; Horton KL; Riu F; Batson J; Amoaku W; Morris JC; Arkill KP; Bates DO
Am J Physiol Heart Circ Physiol; 2022 Jun; 322(6):H1014-H1027. PubMed ID: 35302878
[TBL] [Abstract][Full Text] [Related]
3. Targeting alternative splicing as a new cancer immunotherapy-phosphorylation of serine arginine-rich splicing factor (SRSF1) by SR protein kinase 1 (SRPK1) regulates alternative splicing of PD1 to generate a soluble antagonistic isoform that prevents T cell exhaustion.
Wahid M; Pratoomthai B; Egbuniwe IU; Evans HR; Babaei-Jadidi R; Amartey JO; Erdelyi V; Yacqub-Usman K; Jackson AM; Morris JC; Patel PM; Bates DO
Cancer Immunol Immunother; 2023 Dec; 72(12):4001-4014. PubMed ID: 37973660
[TBL] [Abstract][Full Text] [Related]
4. Altered VEGF Splicing Isoform Balance in Tumor Endothelium Involves Activation of Splicing Factors Srpk1 and Srsf1 by the Wilms' Tumor Suppressor Wt1.
Wagner KD; El Maï M; Ladomery M; Belali T; Leccia N; Michiels JF; Wagner N
Cells; 2019 Jan; 8(1):. PubMed ID: 30641926
[TBL] [Abstract][Full Text] [Related]
5. Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer.
Mavrou A; Brakspear K; Hamdollah-Zadeh M; Damodaran G; Babaei-Jadidi R; Oxley J; Gillatt DA; Ladomery MR; Harper SJ; Bates DO; Oltean S
Oncogene; 2015 Aug; 34(33):4311-9. PubMed ID: 25381816
[TBL] [Abstract][Full Text] [Related]
6. SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from Pro-angiogenic to Anti-angiogenic Isoform.
Hatcher JM; Wu G; Zeng C; Zhu J; Meng F; Patel S; Wang W; Ficarro SB; Leggett AL; Powell CE; Marto JA; Zhang K; Ki Ngo JC; Fu XD; Zhang T; Gray NS
Cell Chem Biol; 2018 Apr; 25(4):460-470.e6. PubMed ID: 29478907
[TBL] [Abstract][Full Text] [Related]
7. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis.
Nowak DG; Amin EM; Rennel ES; Hoareau-Aveilla C; Gammons M; Damodoran G; Hagiwara M; Harper SJ; Woolard J; Ladomery MR; Bates DO
J Biol Chem; 2010 Feb; 285(8):5532-40. PubMed ID: 19906640
[TBL] [Abstract][Full Text] [Related]
8. The control of alternative splicing by SRSF1 in myelinated afferents contributes to the development of neuropathic pain.
Hulse RP; Drake RA; Bates DO; Donaldson LF
Neurobiol Dis; 2016 Dec; 96():186-200. PubMed ID: 27616424
[TBL] [Abstract][Full Text] [Related]
9. SRPK1 inhibition in vivo: modulation of VEGF splicing and potential treatment for multiple diseases.
Oltean S; Gammons M; Hulse R; Hamdollah-Zadeh M; Mavrou A; Donaldson L; Salmon AH; Harper SJ; Ladomery MR; Bates DO
Biochem Soc Trans; 2012 Aug; 40(4):831-5. PubMed ID: 22817743
[TBL] [Abstract][Full Text] [Related]
10. WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing.
Amin EM; Oltean S; Hua J; Gammons MV; Hamdollah-Zadeh M; Welsh GI; Cheung MK; Ni L; Kase S; Rennel ES; Symonds KE; Nowak DG; Royer-Pokora B; Saleem MA; Hagiwara M; Schumacher VA; Harper SJ; Hinton DR; Bates DO; Ladomery MR
Cancer Cell; 2011 Dec; 20(6):768-80. PubMed ID: 22172722
[TBL] [Abstract][Full Text] [Related]
11. Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma.
Gammons MV; Lucas R; Dean R; Coupland SE; Oltean S; Bates DO
Br J Cancer; 2014 Jul; 111(3):477-85. PubMed ID: 25010863
[TBL] [Abstract][Full Text] [Related]
12. Development of Potent, Selective SRPK1 Inhibitors as Potential Topical Therapeutics for Neovascular Eye Disease.
Batson J; Toop HD; Redondo C; Babaei-Jadidi R; Chaikuad A; Wearmouth SF; Gibbons B; Allen C; Tallant C; Zhang J; Du C; Hancox JC; Hawtrey T; Da Rocha J; Griffith R; Knapp S; Bates DO; Morris JC
ACS Chem Biol; 2017 Mar; 12(3):825-832. PubMed ID: 28135068
[TBL] [Abstract][Full Text] [Related]
13. Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMD.
Gammons MV; Fedorov O; Ivison D; Du C; Clark T; Hopkins C; Hagiwara M; Dick AD; Cox R; Harper SJ; Hancox JC; Knapp S; Bates DO
Invest Ophthalmol Vis Sci; 2013 Sep; 54(9):6052-62. PubMed ID: 23887803
[TBL] [Abstract][Full Text] [Related]
14. FGF-2 promotes angiogenesis through a SRSF1/SRSF3/SRPK1-dependent axis that controls VEGFR1 splicing in endothelial cells.
Jia T; Jacquet T; Dalonneau F; Coudert P; Vaganay E; Exbrayat-Héritier C; Vollaire J; Josserand V; Ruggiero F; Coll JL; Eymin B
BMC Biol; 2021 Aug; 19(1):173. PubMed ID: 34433435
[TBL] [Abstract][Full Text] [Related]
15. Serine-Arginine Protein Kinase 1 (SRPK1): a systematic review of its multimodal role in oncogenesis.
Duggan WP; O'Connell E; Prehn JHM; Burke JP
Mol Cell Biochem; 2022 Oct; 477(10):2451-2467. PubMed ID: 35583632
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of SRPK1, a key splicing regulator, exhibits antitumor and chemotherapeutic-sensitizing effects on extranodal NK/T-cell lymphoma cells.
He C; Liu B; Wang HY; Wu L; Zhao G; Huang C; Liu Y; Shan B; Liu L
BMC Cancer; 2022 Oct; 22(1):1100. PubMed ID: 36303126
[TBL] [Abstract][Full Text] [Related]
17. Splicing kinase SRPK1 conforms to the landscape of its SR protein substrate.
Aubol BE; Jamros MA; McGlone ML; Adams JA
Biochemistry; 2013 Oct; 52(43):7595-605. PubMed ID: 24074032
[TBL] [Abstract][Full Text] [Related]
18. Identification of hot spot residues on serine-arginine protein kinase-1 by molecular dynamics simulation studies.
Chandra A; Goyal N; Qamar I; Singh N
J Biomol Struct Dyn; 2021 Mar; 39(5):1579-1587. PubMed ID: 32093544
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus type 16 infection activates the host serine arginine protein kinase 1 (SRPK1) - splicing factor axis.
Mole S; Faizo AAA; Hernandez-Lopez H; Griffiths M; Stevenson A; Roberts S; Graham SV
J Gen Virol; 2020 May; 101(5):523-532. PubMed ID: 32182205
[TBL] [Abstract][Full Text] [Related]
20. SRPK1 and Clk/Sty protein kinases show distinct substrate specificities for serine/arginine-rich splicing factors.
Colwill K; Feng LL; Yeakley JM; Gish GD; Cáceres JF; Pawson T; Fu XD
J Biol Chem; 1996 Oct; 271(40):24569-75. PubMed ID: 8798720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]